AAM Comments on End of Year Funding Bill
Encourages Congress to pass critically important healthcare provisions WASHINGTON, DC (December 18, 2024) – The Association for Accessible Medicines, the trade association for generic and biosimilar manufacturers, today commented on the positive policy developments within the Congressional continuing resolution. “The healthcare provisions in the year-end funding bill are a double win—streamlining patient access to affordable […]
GDUFA and BsUFA User Fees
What are GDUFA and BsUFA user fees? Watch this this video to learn more about how the Generic Drug User Fee Amendments (GDUFA) and Biosimilar User Fee Act (BsUFA) help to get more generic and biosimilar medicines to patients more quickly. Over ten years, the generic and biosimilar industry has provided the FDA over $4 billion […]
AAM Statement on House Energy and Commerce Health Subcommittee Markup of H.R. 7667 Reauthorizing Generic Drug and Biosimilar User Fee Amendments
The Association for Accessible Medicines (AAM) greatly appreciate the leadership of Chairman Pallone, Ranking Member McMorris Rodgers, Chairwoman Eshoo and Ranking Member Guthrie and applaud them for advancing the Food and Drug Amendments of 2022 Act (H.R. 7667), legislation to reauthorize the FDA’s user fee programs for an additional five years. The FDA 2022 Act […]
AAM Statement on FDA User Fee Reauthorization
WASHINGTON D.C. (February 2, 2022) – AAM strongly supports congressional reauthorization of GDUFA and BsUFA as negotiated and without changes. Timely approval of the FDA user fee agreements will ensure that patients continue to benefit from new, more affordable generic and biosimilar medicines. GDUFA III and BsUFA III are the culmination of months of negotiations, […]
AAM Applauds House Passage of FDA User Fee Reauthorization
Calls on Senate to Send Measure to President Trump’s Desk WASHINGTON, DC (July 12, 2017) – The Association for Accessible Medicines (AAM) today applauds the passage of H.R. 2430, the FDA Reauthorization Act of 2017 through the House of Representatives and urges the Senate to take action on the legislation immediately to ensure the timely reauthorization […]
AAM Statement on Senate Passage of FDA User Fee Reauthorization (FDARA)
WASHINGTON, DC (AUGUST 3, 2017) – The Association for Accessible Medicines (AAM) today applauds the leadership of Senator Lamar Alexander (R-TN) Sen. Patty Murray (D-WA), Sen. Susan Collins (R-ME), Sen. Claire McCaskill (D-MO) and Sen. Al Franken (D-MN), and thanks the United States Senate for overwhelmingly passing the FDA Reauthorization Act of 2017 (FDARA) by […]
Statement on Timing of FDA User Fee Reauthorization (FDARA)
WASHINGTON, DC (AUGUST 1, 2017) – The Association for Accessible Medicines (AAM) urges the United States Senate to consider and pass the FDA Reauthorization Act of 2017 (FDARA) as soon as possible. We are encouraged by Majority Leader Mitch McConnell’s (R-KY) remarks earlier today that he wants his colleagues to complete action on the FDARA […]
